Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

634 ARTÍCULOS , VIENDO DEL 121 AL 135

The 25-Year Evolution of Lithium as a Disease-Modifying Agent in Dementia: A Narrative Review

Moore GJ, Bose N, Henter ID, Manji HK.

JAMA Psychiatry. 2026 Sep 1;83(9):976-986. doi: 10.1001/jamapsychiatry.2026.1296.

Cannabinoids Treatment for Agitation in Alzheimer's Disease: A Systematic Review and Meta-Analysis With Bayesian and Sequential Trial Analyses

da Silva AMP, de Siqueira Lima DV Jr, Figueiroa Souza R, Lopes VHP, Januario Campos Cardoso L, Ornelas Pinto EL, Gonçalves OR, Braga C, Cal H, Haddad DS, Vasconcelos SMM, Duarte FS, Perry G, Anghinah R.

Am J Geriatr Psychiatry. 2026 Sep;34(9):1167-1183. doi: 10.1016/j.jagp.2026.05.016. Epub 2026 May 29.

Targeted Treatment of Agitation in Alzheimer's Dementia: Prioritizing Function and Safety Over Sedation and Other Serious Harms

Tariot PN, Citrome L, Clevenger CK, Jackson WC, Montano CB, Patel A, Porsteinsson AP, Sabbagh M.

Prim Care Companion CNS Disord. 2026 Sep 22;28(5):haadachi2603. doi: 10.4088/PCC.haadachi2603.

Immunotherapy with a short-lived anti-PD-L1 antibody in Alzheimer's disease: a phase 1b, randomized, double-blind trial

Croese T, Mummery CJ, Bregman N, Bracha D, Baruch K, Kertser A, Raveh S, Shochat E, Schwartz M.

Nat Med. 2026 Sep;32(9):3458-3465. doi: 10.1038/s41591-026-04547-8. Epub 2026 Jul 15.

Do sigma-1 receptor agonists offer therapeutic promise for Alzheimer's disease?

Panza F, Dibello V, Daniele A, Lozupone M.

Expert Opin Pharmacother. 2026 Aug;27(12):1243-1250. doi: 10.1080/14656566.2026.2706070. Epub 2026 Jul 20.

Acitretin-inspired medicinal chemistry for Alzheimer's disease: A biomarker-gated central nervous system (CNS) discovery framework

Qin TG, Han Y.

Drug Discov Ther. 2026 Sep 21;20(4):349-353. doi: 10.5582/ddt.2026.01054. Epub 2026 Aug 18.

Emerging diagnostic biomarkers and therapeutic targets in Alzheimer's disease

Dineshbhai TK, Rafaliya D, Singh A, Maheshwari S, Lalan M, Chakraborthy GS.

Inflammopharmacology. 2026 Sep;34(9):6003-6034. doi: 10.1007/s10787-026-02341-z. Epub 2026 Aug 22.

Rethinking tau-targeted therapy in Alzheimer's disease: Toward a dual biomarker strategy

Teunissen CE, Pini L, Imbimbo BP.

Alzheimers Dement. 2026 Sep;22(9):e71867. doi: 10.1002/alz.71867.

Overview in Electrochemical and Electrical Biosensors for Determining Blood Protein Biomarkers of Alzheimer's Disease

Gao F, Liu L, Li J, Chen S, Yi X.

Biosensors (Basel). 2026 Aug 6;16(8):426. doi: 10.3390/bios16080426.

Classification accuracies of plasma ptau217 vs. ptau217/Aβ1-42 for brain Aβ pathology in cognitively normal older adults

Olvera-Rojas M, Solis-Urra P, Fernandez-Gamez B, Coca-Pulido A, Triviño-Ibáñez EM, Zeng X, Oberlin LE, Gispert JD, Erickson KI, Gómez-Río M, Karikari TK, Ortega FB, Esteban-Cornejo I.

Geroscience. 2026 Aug;48(4):5695-5708. doi: 10.1007/s11357-025-01967-1. Epub 2025 Nov 6.

Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial

Fleisher AS, Munsie L, Mancini M, Cheng YJ, Guo J, Nuthall H, Otero DS, Kotari V, Kielbasa W, Hutton M, Brys M, Mergott DJ, Mintun M, Hansson O.

JAMA. 2026 Sep 22;336(12):1017-1028. doi: 10.1001/jama.2026.12768.

More efficient screening for preclinical Alzheimer's clinical trials using mixture of experts

Langford O, Raman R, Aisen P, Sperling R, Johnson K, Molina-Henry D, Sachdev P, Li D, Jimenez-Maggiora GA, Johnson SC, Braunstein JB, Birkenbihl C, Cuppels M, Buckley RF, Rissman RA, Donohue MC.

Alzheimers Dement. 2026 Sep;22(9):e71681. doi: 10.1002/alz.71681.

Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes

Hey JA, Abushakra S, Power A, Watson D, Porsteinsson A, Sabbagh M, MacSweeney E, Cohen S, Boada M, Doraiswamy PM, Elahi FM, Rissman RA, Liang E, Flint S, Hristova E, Kesslak P, McLaine R, Albayrak A, Schaefer JF, Yu JY, Tolar L, Tolar M.

Drugs. 2026 Oct;86(10):1705-1721. doi: 10.1007/s40265-026-02381-3. Epub 2026 Sep 1.

Small nucleolar RNAs: Emerging therapeutic and diagnostic frontiers in Alzheimer's disease

Sharma T, Sharma P, Bashir B, Singh SK, Vishwas S.

Drug Discov Today. 2026 Sep;31(5):104771. doi: 10.1016/j.drudis.2026.104771. Epub 2026 Aug 14.

Operationalizing Alzheimer's disease trials in the era of targeted therapies

Pillai JA, Alladi S, Appleby BS, Brosch JR, Frederiksen KS, Galasko D, Lopez OL, Leverenz JB, Saykin AJ, Schott JM, Seshadri S, Tousi B, Wolk DA.

Alzheimers Dement. 2026 Sep;22(9):e71829. doi: 10.1002/alz.71829.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias